Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril

Abstract

Abstract: Objective To explore the relationship between angiotensin converting enzyme (ACE) (I/D) gene polymorphism and the level of high-sensitivity C-reactive protein (hsCRP) in type 2 diabetic patients with atherosclerosis treated with ramipril. Methods A total of 118 in type 2 diabetic patients with atherosclerosis aged 35 years or older without clinical proteinuria, heart failure, or low ejection fraction (<40%), who were not taking ACE inhibitors or (ARB), were randomized into two groups to receive treatment with ramipril (ACEI group, beginning with 2.5 mg/d till reaching 5 mg/d) or placebo for 3 months. The 99 patients in ACEI group were further divided into 3 subgroups according to ACE (I/D) genotypes DD, ID and II, each group consisting of at least 20 patients. The level of hsCRP was detected by enzyme-linked immunosorbent assay before and after the therapy. Result and Conclusion After therapy, hsCRP level significantly decreased, but hsCRP levels showed no significant differences between the groups of different ACE genotypes.

CLC Number:

WANG Ling, ZHOU Ying-ling, LIN Shu-guang. Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril[J]. Journal of Southern Medical University, 2005, 25(06): 691-695.

References

[1] (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy Heart Outcomes Prevention Evaluation [J]. Lancet, 2000, 355:253-8.
[2] Anderson JL, Carlquist JF, Home BD, et al. Cardiovascular pharmacoge-nomics:current status, future prospects [J]. J Cardiovasc Pharmacol Ther, 2003, 8(1):71-83.
[3] Mcnamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensinconverting enzyme deletion polymorphism in patients with congestive heart failure[J]. Circulation, 2001, 103(12):1608-10.
[4] Baudin B. Angiotensin I-converting enzyme gene polymorphism and drug response[J]. Clin Chem Lab Med, 2000, 38(9):853-6.
[5] Tetickovic E, Gajsek-Marchetti M, Matela J, et al. Three dimensional ultra-songraphy for the evaluation of atherosclerotic stenosis of the carotid trunk[J]. Coll Antropol, 2001, 25(2):511-20.
[6] Crouse JR, Harpold GH, Kahl FR, et al. Evaluation of scoring system for extracanial carotid atherosclerosis extent with B-mode ultrasound[J]. Stroke, 1986, 17(3):270-4.
[7] Harry Y, Rifai N. High sensitivity C-reactive protein and atherosclerosis:from theory to therapy [J]. Clin Biochem, 2000, 33 (8):601-10.
[8] Ikonom idis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in. patients with chronic stable angina and their reduction by aspirin [J]. Circulation, 1999, 100(8):793-8.
[9] Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastationt on plasma concentntion of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators [J].Circulation, 1999, 100(3):230-5.
[10] Libby P, Ridker PM. Inflammation and atherosclerosis:role of Creactive protein risk assessment [J]. Am J Med, 2004, 116(Suppl6A):95-165.
[11] Labarrere CA, Zaloga GP. C-reactive protein:from innocent bystander to pivotal mediator of atherosclerosis [J]. Am J Med, 2004,117:499-507.
[12] Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med, 2002, 347(20):1557-65.
[13] Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease[J]. J Am Coll Cardiol, 2004, 44(2):362-8.
[14] 李宏芬,沈志霞,常延河,等.中国人群血管紧张素转换酶基因与血管紧张素Ⅱ-Ⅰ型受体基因A1166-C单核苷酸多态性分析[J].中华检验医学杂志,2003,26(2):89-92.Li HF, Shen ZX, Chang YH, et al. Distribution of polymorphism of angiotensin converting enzyme gene and A1 16-C single nucleotide polymorphism of angiotensin Ⅱ type Ⅰ receptor gene in normal Chinese [J]. Chin J Lab Med, 2003, 26(2):89-92.
[15] Evans WE, Relling MV. Pharmacogenomics:translating functional genomics into rational therapeutics[J]]. Science, 1999, 286(5439):487-91.
[16] Prasad A, Narayanan S, Husain S, et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition [J]. Circulation, 2000, 102(1):35-41.
[17] Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin Ⅰ-coverting enzyme (ACE) gene controls plasma ACE levels [J].Am J Hum Genet, 1992, 51(1):197-205.